- Home
- SQNS vs APLT Comparison
SQNS vs APLT Comparison
Compare SQNS & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQNS
- APLT
- Stock Information
- Founded
- SQNS 2003
- APLT 2016
- Country
- SQNS France
- APLT United States
- Employees
- SQNS N/A
- APLT N/A
- Industry
- SQNS Semiconductors
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- SQNS Technology
- APLT Health Care
- Exchange
- SQNS Nasdaq
- APLT Nasdaq
- Market Cap
- SQNS 147.0M
- APLT 63.6M
- IPO Year
- SQNS 2011
- APLT 2019
- Fundamental
- Price
- SQNS $9.52
- APLT $0.41
- Analyst Decision
- SQNS Buy
- APLT Buy
- Analyst Count
- SQNS 1
- APLT 6
- Target Price
- SQNS $3.50
- APLT $6.10
- AVG Volume (30 Days)
- SQNS 4.0M
- APLT 771.9K
- Earning Date
- SQNS 11-04-2025
- APLT 11-06-2025
- Dividend Yield
- SQNS N/A
- APLT N/A
- EPS Growth
- SQNS N/A
- APLT N/A
- EPS
- SQNS 18.54
- APLT N/A
- Revenue
- SQNS $37,325,000.00
- APLT $121,000.00
- Revenue This Year
- SQNS N/A
- APLT N/A
- Revenue Next Year
- SQNS $89.05
- APLT $5,931.24
- P/E Ratio
- SQNS $0.52
- APLT N/A
- Revenue Growth
- SQNS 32.07
- APLT N/A
- 52 Week Low
- SQNS $0.73
- APLT $0.30
- 52 Week High
- SQNS $9.72
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- SQNS 95.31
- APLT 38.50
- Support Level
- SQNS $0.93
- APLT $0.40
- Resistance Level
- SQNS $0.89
- APLT $0.46
- Average True Range (ATR)
- SQNS 0.10
- APLT 0.03
- MACD
- SQNS 0.60
- APLT -0.01
- Stochastic Oscillator
- SQNS 97.77
- APLT 7.74
About SQNS Sequans Communications S.A.
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.